Back to News
Market Impact: 0.22
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Source: globenewswire.com
Healthcare & Biotech

A peer-reviewed pilot study reported an 83.3% response rate and 50% remission rate for depressive symptoms, alongside measurable changes in brain activity and connectivity. The findings are encouraging for the underlying treatment approach, but the pilot-scale nature of the study limits near-term commercial and market implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal